Diana D Kang, Xucheng Hou, Leiming Wang, Yonger Xue, Haoyuan Li, Yichen Zhong, Siyu Wang, Binbin Deng, David W McComb, Yizhou Dong
Since the approval of the lipid nanoparticles (LNP)-mRNA vaccines against the SARS-CoV-2 virus, there has been an increased interest in the delivery of mRNA through LNPs. However, current LNP formulations contain PEG lipids, which can stimulate the generation of anti-PEG antibodies. The presence of these antibodies can potentially cause adverse reactions and reduce therapeutic efficacy after administration. Given the widespread deployment of the COVID-19 vaccines, the increased exposure to PEG may necessitate the evaluation of alternative LNP formulations without PEG components...
July 2024: Bioactive Materials